secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001193805-22-001472
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic Q3 net loss $21.2M; goodwill impairment ~$33M; cash $129M; IMU-935 psoriasis trial misses
--------------------------------------------------------------------------------

- Net loss $21.2M ($0.69/share) vs $19.3M ($0.76) in Q3 2021; R&D $16.5M, G&A $3.6M.
- Cash $72.8M at Sept 30; plus $56.4M net from Oct private placement => runway into Q4 2024.
- Expects goodwill impairment of ~$33M in Q4 2022 due to stock decline after IMU-935 psoriasis data.
- IMU-935 psoriasis phase 1b: interim data showed no separation from placebo; high placebo rate; update Q1 2023.
- IMU-856 phase 1 Parts A/B positive; Part C in celiac disease ongoing, data 2023; patent allowance received.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380522001472/0001193805-22-001472-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380522001472/e617987_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-22-001472

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer